While SGLT-2 inhibitors alone do not cause significant hypoglycemia, this risk can be increased in patients on concurrent insulin and sulfonylureas, and it may be beneficial for patients’ primary diabetes mellitus management team to be involved in these cases [10]. The gene discussed is INS; the disease is diabetes mellitus.